Tags : Triple Combination Therapy

Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for

Shots: The P-III COSMIC-313 study involves assessing of Cabometyx (cabozantinib) + Opdivo (nivolumab) + Yervoy (ipilimumab) vs nivolumab+ ipilimumab + PBO in 676 patients in the ratio (1:1) with previously untreated advanced RCC across 150 sites globally The P-III COSMIC-313 study follows ongoing P-Ib study assessing cabozantinib + nivolumab with/without ipilimumab in patients with advanced […]Read More